Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

ARCA biopharma Announces Clinical Trial Agreement for GENETIC-AF Trial



  ARCA biopharma Announces Clinical Trial Agreement for GENETIC-AF Trial

  Gencaro Potentially the First Genetically-Targeted AF Prevention Treatment

Business Wire

WESTMINSTER, Colo. -- November 6, 2013

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing
genetically-targeted therapies for cardiovascular diseases, and Duke
University’s Duke Clinical Research Institute (DCRI), the world’s largest
academic clinical research organization (ARO), today announced a new agreement
under which ARCA and the DCRI will work together to execute GENETIC-AF, a
planned Phase 2B/3 genetically-targeted, comparative effectiveness clinical
trial evaluating Gencaro™ (bucindolol hydrochloride) as a potential treatment
for the prevention of atrial fibrillation (AF) in patients with heart failure.
Patient enrollment in GENETIC-AF is expected to begin in the first quarter of
2014.

ARCA has identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential to be the
first genetically-targeted therapy for the prevention of AF.

The DCRI will serve as the coordinating center and principal investigator for
GENETIC-AF. The DCRI has substantial experience in conducting multicenter
trials in atrial fibrillation, having been the ARO for several large recently
completed AF trials, which had a combined enrollment of more than 32,000 AF
patients.

GENETIC-AF Clinical Trial

GENETIC-AF is planned as a Phase 2B/3, multi-center, randomized, double-blind
clinical trial comparing Gencaro to Toprol-XL for prevention of AF in patients
with heart failure and/or reduced left ventricular ejection fraction (HFREF).
ARCA plans to enroll only patients with the genetic variant of the beta-1
cardiac receptor which the Company believes responds most favorably to
Gencaro. GENETIC-AF has an adaptive design, under which the Company plans to
initiate a Phase 2B trial in approximately 200 patients and then, depending on
the results of an interim analysis by the trial Data Safety Monitoring Board
(DSMB), transition the trial to a Phase 3 trial with the enrollment of
approximately 420 additional patients. The Company anticipates that patient
enrollment in GENETIC-AF will begin in the first quarter of 2014.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for
cardiovascular diseases. The Company's lead product candidate, Gencaro^TM
(bucindolol hydrochloride), is an investigational, pharmacologically unique
beta-blocker and mild vasodilator being developed for atrial fibrillation.
ARCA has identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential to be the
first genetically-targeted therapy for the prevention of atrial fibrillation.
ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF
trial. For more information please visit www.arcabiopharma.com.

About Duke Clinical Research Institute (DCRI)

The Duke Clinical Research Institute, a department of Duke University, is the
world’s largest academic clinical research organization and is known for
conducting groundbreaking multinational clinical trials, managing major
national patient registries, and performing landmark outcomes research. The
DCRI has worked with more than 14,000 investigators at nearly 37,000 sites in
65 countries. The DCRI has conducted more than 970 Phase I–IV studies and
outcomes research projects with a combined enrollment of more than 1.2 million
patients. The DCRI’s legacy of research has generated more than 8,300
publications in peer-reviewed journals.

Safe Harbor Statement

This press release contains "forward-looking statements" for purposes of the
safe harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements regarding,
potential timing for patient enrollment in the GENETIC-AF trial, the potential
for genetic variations to predict individual patient response to Gencaro,
Gencaro’s potential to treat atrial fibrillation, future treatment options for
patients with atrial fibrillation, the significance of the DCRI’s experience
in clinical trial management on the execution and outcome of GENETIC-AF and
the potential for Gencaro to be the first genetically-targeted atrial
fibrillation prevention treatment. Such statements are based on management's
current expectations and involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including, without
limitation, the risks and uncertainties associated with: the Company's
financial resources and whether they will be sufficient to meet the Company's
business objectives and operational requirements; results of earlier clinical
trials may not be confirmed in future trials, the protection and market
exclusivity provided by the Company’s intellectual property; risks related to
the drug discovery and the regulatory approval process; and, the impact of
competitive products and technological changes. These and other factors are
identified and described in more detail in ARCA’s filings with the SEC,
including without limitation the Company’s annual report on Form 10-K for the
year ended December 31, 2012, and subsequent filings. The Company disclaims
any intent or obligation to update these forward-looking statements.

Contact:

ARCA biopharma, Inc.
Derek Cole, 720-940-2163
Investor Relations
derek.cole@arcabiopharma.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement